血清AACT在前列腺癌早期诊断中的作用研究OA

Objective To investigate the expression,diagnostic efficacy,and clinical significance of α1-antichymotrypsin(AACT)encoded by SERPINA3 in prostate cancer(PCa).Methods Publicly-available database analysis evaluated SERPINA3 expression and its correlation with clinical features.Serum samples from treatment-naïve PCa patients,benign prostatic hyperplasia(BPH)patients and healthy controls collected at Zhongnan Hospital of Wuhan University were analyzed via ELISA for AACT expression levels.The receiver operating characteristic curve and its area under the curve(AUC)were assessed for diagnostic performance.ssGSEA analyzed associations between SERPINA3 expression and pro-oncogenic pathways using TCGA data.Results SERPINA3 expression was significantly elevated in PCa patients versus controls(P<0.05).ELISA revealed higher serum AACT levels in PCa compared to BPH patients(P<0.001).The AUC value of distinguishing PCa from BPH and healthy control was 0.968[95％CI(0.930,0.998)]and 0.958[95％CI(0.910,0.994)],respectively.ssGSEA demonstrated strong correlations between SERPINA3 and pro-tumor pathways(apoptosis,DNA repair,metabolism)(P<0.001).Conclusion Serum AACT exhibits high clinical potential for early PC diagnosis.